Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and purpose</h3><p>PD‐1/PD‐L1 antibodies have achieved great success in clinical treatment. However, monoclonal antibody drugs also have challenges, such as high manufacturing costs, poor diffusion, low oral bioavailability, and limited penetration into tumor tissue. The development of small‐molecule inhibitors of PD‐1/PD‐L1 interaction represents a promising perspective to overcome the above challenges in cancer immunotherapy.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental approach</h3><p>We explored structural activity relationships and used biochemical assays to generate a lead compound (ZE132). CD8+T cells killing assay and <i>Ifng</i> expression assay were used to verify the <i>in vitro</i> cellular activity of ZE132. Off‐target study was performed to verify the selectivity. </p><p>Syngeneic mouse models were used to verify the <i>in vivo</i> activity of ZE132 in tumor immune microenvironment (TIME). We also performed pharmacokinetics (PK) profiling in mice and The Cancer Genome Atlas (TCGA) database analysis. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key results</h3><p>ZE132 can effectively inhibits the PD‐1/PD‐L1 interactions <i>in vitro</i>, and it has a potent affinity to PD‐L1. ZE132 shows robust anti‐tumor effects <i>in vivo</i>, better than anti‐PD‐1 antibody. In the analysis of TIME, we found that ZE132 treatment promotes cytotoxic T‐cell tumor infiltration and induces IL‐2 expression. In addition, ZE132 elicits strong inhibitory effects on the mRNA expression of TGF‐β, which may serve as a potential biomarker to predict responsiveness to PD‐1/PD‐L1 immunotherapies. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion and implications</h3><p>We identified a new lead compound ZE132 targeting PD‐1/PD‐L1 interactions, not only showing favorable drug‐like properties <i>in vitro</i> and <i>in vivo</i>, but also showing the advantage of overcoming the barrier of TIME compared to anti‐PD‐1 antibody. </p></section>

Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.

Design, Synthesis, and Anticancer Activity Evaluation of Hybrids of Azoles and Barbituric Acids.

Design, synthesis and structure-activity relationship of malonic acid non-nucleoside derivatives as potent CD73 inhibitors

Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1 H,3 H)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5'-nucleotidase

Design, synthesis and cytotoxic evaluation of novel betulonic acid-diazine derivatives as potential antitumor agents

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity

Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy

Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds

Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors

Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual Immunotherapy

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction

Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage

Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73

Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors

Discovery of Novel Benzimidazole Derivatives As Potent P300 Bromodomain Inhibitors with Anti-Proliferative Activity in Multiple Cancer Cells.

Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8h)-one Derivatives As Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Optimization of Benzamide Derivatives As Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site.

Discovery of a novel, potent and selective small‐molecule inhibitor of PD‐1/PD‐L1 interaction with robust in vivo anti‐tumour efficacy

Synthesis and Evaluation of a Novel Small-molecule Compound As an Anticancer Inhibitor of CD147.

Discovery of Pyridinone Derivatives As Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy